BBA
FTH

Baker Bros. Advisors’s Faeth Therapeutics FTH Stock Holding History

Baker Bros. Advisors’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2M Buy
+1,286,411
New +$29.8M 0.16% 44

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Baker Bros. Advisors's FTH Position: Q2 2026 in Review

Baker Bros. Advisors opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 1,286,411 shares worth $32.2M. The stake represents 0.16% of the portfolio and ranks #44 among its holdings.

45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Baker Bros. Advisors held 1,286,411 shares of Faeth Therapeutics worth $32.2M as of Q2 2026.
  • Faeth Therapeutics was a new Baker Bros. Advisors position in Q2 2026.
  • Faeth Therapeutics made up 0.16% of Baker Bros. Advisors's portfolio in Q2 2026, its #44 holding.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.